Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

• Status: Terminated
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Endo Pharmaceuticals
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• histologically confirmed tumor

• documented evidence of carcinoid syndrome

• life expectancy of at least 6 months

• previous positive octreotide scan

• received stable doses of octreotide injections

• performance status of 0-2 on the ECOG performance scale

Exclusion Criteria:

• poorly differentiated or high grade neuroendocrine tumor

• significant cv, hepatic, renal or other disease